EFFECTIVENESS AND SAFETY OF SOFOSBUVIR AND DACLATASVIR COMBINATION FOR THETREATMENT OF HEPATITIS C | Journal of Postgraduate Medical Institute 2019

Author(s)

Dilaram Khan Department of Gastroenterology,Lady Reading Hospital,Peshawar, Pakistan

Fakhre Alam Department of Gastroenterology,Lady Reading Hospital,Peshawar, Pakistan

Mohammad Iltaf Department of Gastroenterology,Lady Reading Hospital,Peshawar, Pakistan

Muhammad Kamran Hassan Department of Gastroenterology,Lady Reading Hospital,Peshawar, Pakistan

Hashmatullah Khan Department of Gastroenterology, Lady Reading Hospital, Peshawar, Pakistan

Amir Ghafoor Department of Gastroenterology,Lady Reading Hospital,Peshawar, Pakistan

Abstract

To determine the effectiveness and safety of sofosbuvir and daclatsvir combination for the treatment of hepatitis C. Methodology: This study, of 145 patients, was done in the OPDs of Gastroenterology Unit, LRH & HMC of Khyber Pakhtunkhwa, from January 1st 2017 to December 1st, 2017. HCV infected Patients aged more than 18 years, of either gender, irrespective of previous treatment status having normal hematological tests and ultrasound were included. Results: Ninty three patients (64.13%) were male and 52 (35.86%) female. Mean age was 39.27 ±10.95. Genotype 3 was the most common genotype, present in 130 (89.65%) patients. All patients with HCV Genotype 3, Genotype 2 and Genotype 1 and untypeable had undetectable HCV RNA at week 4, while 122 (93.84%) patients with HCV Genotype 3; 6(85.71%) patients with Genotype 2; and 4(100%) each with Genotype 1 and untypeable had undetectable HCV RNA twelve weeks after treatment completion. Ten (6.89%) patients developed fatigue, 9(6.20%) patients developed nausea while 8(5.51) patients complained of headache. Conclusion: Combination of sofosbuvir and daclatasvir was found highly effective with high safety profile in HCV infected patients in our set up.

Publication Details

Page(s) 19-22

DOI DOI not available

Published Journal: Journal of Postgraduate Medical Institute, Volume: 33, Issue: 1, Year: 2019

Keywords

Sofosbuvir hepatitis C Daclatasvir

References

References are not available for this document.

Citations

Citations are not available for this document.